Dicot AB recently entered phase I with its drug candidate LIB-01, where the first step is to test single dosing on healthy volunteers. In parallel, the company is now starting the second part of the study, testing repeated dosing of the candidate. The first results from the study are expected in the spring.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2495 SEK | +4.83% | +19.09% | -21.54% |
Apr. 23 | Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study | CI |
Mar. 11 | Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial | CI |
1st Jan change | Capi. | |
---|---|---|
-21.54% | 18.59M | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- DICOT Stock
- News Dicot AB
- Dicot AB Initiates Repeated Dosing in Phase I Study